You can read the full March 20th print issue of Chain Drug Review in its entirety here. In CDR’s digital editions, you can find special sections and additional pages not posted online. You will need to register, but subscription is free!
The dispensing of mifepristone, one of two medications used sequentially to terminate pregnancy, has emerged as a very thorny problem for Walgreens, one that will, in short order, engulf other retail pharmacies across the country. The issue burst into prominence at the beginning of February when the attorneys general of 20 states wrote a letter
After three years of the pandemic, consumers are returning to health care. But they are not returning to the same health care landscape, nor are they behaving in the same manner. The pent-up post-pandemic demand for health care services has created longer wait times at traditional point-of-care locations like primary care offices, pushing consumers to
Walgreens (along with CVS, Rite Aid and several regional mass retailers) has been in the news recently, though not for the usual reasons — and not under the most favorable circumstances. Along with other newspapers and periodicals, The New York Times has lately put Walgreens in its cross hairs, with attention-grabbing headlines such as these:
